Cargando…
Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
The prevalence of nonalcoholic fatty liver disease (NAFLD), recently also re-defined as metabolic dysfunction associated fatty liver disease (MAFLD), is rapidly increasing, affecting ~25% of the world population. MALFD/NAFLD represents a spectrum of liver pathologies including the more benign hepati...
Autores principales: | Subramanian, Pallavi, Hampe, Jochen, Tacke, Frank, Chavakis, Triantafyllos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266719/ https://www.ncbi.nlm.nih.gov/pubmed/35805998 http://dx.doi.org/10.3390/ijms23136996 |
Ejemplares similares
-
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022) -
Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020) -
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021) -
Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023) -
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)